Markers of resistance to anti-EGFR therapy in colorectal cancer.
Year: 2013
Type: article
Abstract: Epidermal growth factor receptor (EGFR) is a therapeutic target in colorectal cancer (CRC). The benefit from EGFR inhibitors appears to be limited to a subset of patients with CRC. Mechanisms of resistance to EGFR inhibitors are being identified. KRAS codon 12 activating mutation is a predominate mechanism of resistance to EGFR inhibitors in around 40% of patients with advanced CRC. Other potential mechanisms of resistance include ligand expression, increased EGFR number, mutations of BRAF and activation of alternate signaling pathways.
Source: Europe PMC (PubMed Central)
Authors: Walid Shaib, Reena Mahajan, Bassel El-Rayes
Institutions: Emory University, Winship Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1652638408
